Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792723 | 0.89 | PRKCA (0.49) | PRKCAMMP12NR1I2SCN9ACYP19A1 | |
| SCHEMBL792695 | 0.87 | PRKCA (0.39) | PRKCAMMP12PIK3CAPIK3CBPIK3CG | |
| SCHEMBL14572897 | 0.85 | NR1I2 (0.37) | PRKCAMMP12PIK3CAPIK3CBPIK3CG | |
| SCHEMBL772828 | 0.83 | PRKCA (0.64) | PRKCAMMP12NR1I2SCN9A | |
| SCHEMBL792879 | 0.83 | PRKCA (0.38) | PRKCAMMP12PIK3CAPIK3CBPIK3CG | |
| SCHEMBL772062 | 0.83 | PRKCA (0.55) | PRKCAMMP12PIK3CANR1I2SCN9A | |
| SCHEMBL793023 | 0.83 | PRKCA (0.36) | PRKCAMMP12PIK3CAPIK3CBPIK3CG | |
| SCHEMBL792506 | 0.83 | MAOB (0.47) | PRKCAMMP12 | |
| SCHEMBL772347 | 0.82 | PRKCA (0.54) | PRKCAMMP12PIK3CANR1I2SCN9A | |
| SCHEMBL772608 | 0.82 | PRKCA (0.54) | PRKCAMMP12NR1I2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | PRKCA 2404/4885MMP12 1013/4885PIK3CA 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.